Wells Fargo
KLRS

Wells Fargo’s Kalaris Therapeutics KLRS Stock Holding History

Wells Fargo’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-794
Closed -$13.8K – 7587
2024
Q1 		$13.8K Buy
794
+100
+14% +$1.63K ﹤0.01% 5668
2023
Q4 		$10.9K Buy
694
+135
+24% +$5.32K ﹤0.01% 5819
2023
Q3 		$27.7K Sell
559
-145
-21% -$9.88K ﹤0.01% 5466
2023
Q2 		$55.1K Buy
704
+451
+178% +$42.9K ﹤0.01% 5387
2023
Q1 		$22.9K Buy
253
+244
+2,711% +$31.1K ﹤0.01% 5581
2022
Q4 		$1.03K Sell
9
-24
-73% -$4.07K ﹤0.01% 6182
2022
Q3 		$6K Sell
33
-9
-21% -$1.4K ﹤0.01% 5872
2022
Q2 		$3K Sell
42
-7
-14% -$734 ﹤0.01% 6245
2022
Q1 		$8K Sell
49
-479
-91% -$95.6K ﹤0.01% 6359
2021
Q4 		$157K Buy
528
+527
+52,700% +$244K ﹤0.01% 5400
2021
Q3 		$0 Sell
1
-748
-100% -$346K ﹤0.01% 7655
2021
Q2 		$340K Buy
749
+748
+74,800% +$386K ﹤0.01% 4808
2021
Q1 		$0 Sell
1
-454
-100% -$382K ﹤0.01% 7512
2020
Q4 		$402K Sell
455
-165
-27% -$127K ﹤0.01% 4674
2020
Q3 		$392K Buy
+620
New +$423K ﹤0.01% 4529

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's KLRS Position: Q2 2024 in Review

Wells Fargo sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 794 shares — an estimated $13.8K sold.

Wells Fargo first reported a position in KLRS in Q3 2020 and held it in 15 quarters. The position peaked at $402K in Q4 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Wells Fargo reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 794 Kalaris Therapeutics shares in Q2 2024, an estimated $13.8K.
  • Wells Fargo first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 15 quarters.
  • Wells Fargo's Kalaris Therapeutics position peaked at $402K in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.